Fraile-Ribot, Pablo A.Zamorano, LauraOrellana, RocioDel Barrio-Tofiño, EsterSanchez-Diener, IrinaCortes-Lara, SaraLopez-Causape, CarlaCabot, GabrielBou, GermanMartinez-Martinez, LuisOliver, Antonio2023-02-082023-02-082019-11-14Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19http://hdl.handle.net/10668/14708Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.enPseudomonas aeruginosaAntibiotic resistanceExtensively drug resistantImipenem-relebactamMultidrug resistanceWhole-genome sequencingβ-lactam resistance mechanismsAnti-Bacterial agentsAzabicyclo compoundsColistinHumansImipenemMutationPseudomonas infectionsPseudomonas aeruginosabeta-Lactam Resistancebeta-Lactamasesresearch article31740559open accessAntibacterianosColistinaCompuestos de azabicicloHumanosInfecciones por pseudomonasMutacionPseudomonas aeruginosaResistencia betalactamicabeta-Lactamasas10.1128/AAC.02165-191098-6596PMC6985745https://europepmc.org/articles/pmc6985745?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985745/pdf